Strategic Biomarker Integration
Optimizing Drug Development With Biomarkers
The strategic integration of biomarkers into the drug development process empowers sponsors with critical information at every stage.
Altasciences’ biomarker services provide insight into a drug’s efficacy, safety, and mechanism of action, where we can translate findings into clinical applications and beyond, resulting in reduced timelines.
Our Laboratory Sciences team has the scientific, operational, and regulatory acumen to offer pre-existing validated assays in multiple species and matrices, and can develop new methods to meet your needs.
Is the assay you are looking for missing? Contact us to discuss how we can support your specific needs.
You may also be interested in the below resources:
Fact Sheets
• Flow Cytometry Services
• Immunogenicity Testing
• Immunomodulatory Drugs
eBooks
• Key Biomarkers of Immunomodulation
• Altasciences' Proactive Drug Development Solution: Large Molecules
Poster Presentation
• Immunogenicity Target Interference: A Novel Blocking Approach
Altasciences Has You Covered From Coast to Coast
Accelerate your drug development timelines by up to 40% with an integrated CRO/CDMO by your side, from lead candidate selection to clinical proof of concept, and beyond.
Our scientific and operational teams move in unison to provide a seamless and synchronized drug development roadmap with research activities running in parallel. With nine strategically placed research and manufacturing facilities across North America, Altasciences has the capacity to help you get better drugs to the people who need them, faster.
Preclinical safety studies
per year
Clinical trials
per year
Study samples trials
per year
With multiple points of entry, Altasciences' integrated, full-service solutions help you make educated and more complete early phase drug development decisions. When you choose the right partner, you only need one.
Get a glimpse of the unique expertise at each of our nine facilities: 
You may also be interested in the following:
• Digital Brochure: Our Expertise at a Glance
• Video: Accelerate Your Data With Our Co-Located Clinic and Lab
• Webpage: Proactive Drug Development
• Video: Quick Chat With CEO Chris Perkin: One Operational Structure
Life Science Review: Top Integrated CRO 2024 — Altasciences
Pharmacokinetics, Pharmacodynamics and Toxicokinetics Demystified
Understanding the effects of a drug, and how it interacts with the body, and vice versa, is critical to ensure it is safe for human use. This is where pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) analyses step in.
Discover the Power of Driving Simulations for CNS Side-Effect Analysis
Start Your Driving Trial Quickly—Simulators On-Site
Driving simulator studies are a safe, efficient, and effective alternative to on-the-road driving trials for CNS-active drugs. This issue of The Altascientist dives into the requirements and technicalities of driving studies, and explains how driving simulation offers:
Faster study startup • Lower cost • No risk of property damage • No risk of injuries
This issue includes a case study for which the results were described as “reassuring” by the FDA.
Altasciences has conducted over 13,000 simulated drives in support of drug development.
Download as a PDF or listen to the audiobook; the choice is yours.
You may also be interested in the following:
• Driving Studies Webpage
• Driving Studies Webinar
Altasciences Appoints New General Manager, Clinical Operations
Laval, Québec, Monday, January 29, 2024—Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.
James joined Altasciences, having previously worked as Vice President of Research at Akron Children’s Hospital, and most recently as Vice President of Research Operations for Circuit Clinical.
“James’ proven leadership skills, and deep knowledge of all phases of clinical research, will be invaluable in delivering expert guidance for our clients along their early-phase clinical journey,” said Ingrid Holmes, Vice President, Clinical Operations, Altasciences.
With close to a decade of experience in the healthcare and pharmaceutical sectors, including clinical pharmacology, James will apply his knowledge to oversee the day-to-day management of clinical operations at Altasciences’ 140-bed, Phase I clinical pharmacology unit in Kansas City.
“It is rewarding to be joining a team that has been in place for almost three decades, a team committed to quality, excellence, integrity, and respect—focused on helping to bring better therapies to the patients who need them, faster,” says James.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com